Use of 2.5% polyacrylamide hydrogel mitigates joint capsule stiffness and cartilage degradation in experimental equine osteoarthritis.

Overview

• This study investigated whether injections of 2.5% polyacrylamide hydrogel (iPAAG) could reduce joint stiffness and cartilage damage in a horse model of osteoarthritis (OA).
• Results indicated that iPAAG treatment helped preserve cartilage integrity and maintained normal joint capsule flexibility compared to saline-treated controls.

Study Objectives and Design

• The goal was to evaluate symptom-modifying and disease-modifying effects of injectable 2.5% polyacrylamide gel in experimental equine OA.
• Sixteen horses underwent surgical creation of an osteochondral fragment in one middle carpal joint (a joint in the horse’s wrist) to induce OA.
• Two weeks after surgery (day 14), joints were injected with either 2 mL of phosphate-buffered saline (control group, n=8) or 2.5% iPAAG (treatment group, n=8).
• Starting on day 16, horses were subjected to high-speed treadmill exercise to exacerbate OA development.

Methods of Evaluation

• Clinical parameters measured weekly included:
• Lameness (degree of limping)
• Joint effusion (swelling)
• Range of motion
• Flexion response (pain when bending the joint)
• Synovial fluid samples were collected biweekly to assess joint environment.
• Radiographic imaging of the joints was done pre-surgery, at day 14, and day 70 to monitor structural changes.
• At day 70 post-surgery, horses were euthanized for postmortem evaluations including:
• Gross examination of the joint
• Arthroscopic (minimally invasive camera) evaluation
• Histopathologic (microscopic tissue) analysis of the joint capsule and cartilage
• Measurement of joint capsule stiffness (elasticity)

Key Results

• No significant differences were found between treatment and control groups in clinical symptoms such as lameness or joint swelling during the study.
• Histopathology showed:
• Joints treated with iPAAG had significantly better cartilage health in the third carpal bone, reflected in lower total cartilage lesion scores.
• Proteoglycan staining (indicative of cartilage matrix health) in the intermediate cartilage layer was better preserved in iPAAG-treated joints.
• Joint capsule stiffness measurements revealed:
• Saline-treated OA joints demonstrated increased stiffness (reduced elasticity) compared to the unaffected contralateral joints.
• In contrast, iPAAG-treated joints maintained joint capsule stiffness similar to the contralateral healthy joints, indicating preservation of normal elasticity.

Interpretation and Implications

• While iPAAG did not significantly improve overt clinical symptoms within the study timeframe, it demonstrated protective effects against cartilage degradation at the microscopic level.
• The ability of iPAAG to maintain joint capsule elasticity suggests it may limit stiffness development associated with OA progression.
• This dual action—mitigating cartilage damage and preserving joint capsule flexibility—indicates potential of iPAAG as a disease-modifying treatment for equine OA.

Potential Applications and Future Research

• The findings support further exploration of 2.5% iPAAG injections as a therapeutic option in horses with naturally occurring OA.
• Future studies could assess long-term clinical benefits, optimal dosing, and mechanisms of hydrogel action in reducing joint degeneration.
• Evaluations in naturally diseased joints and across varying OA severities will be important to confirm clinical relevance.